INTRODUCTION
============

Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) worldwide ([@B103]; [@B121]; [@B89]; [@B99]). Current treatment strategies can partially slow the progression of the disease, but completely ceasing the progression of diabetic nephropathy is challenging ([@B66]; [@B12]). Once diabetic nephropathy progresses to ESRD, management with dialysis is associated with increased cardiovascular morbidity and mortality compared to non-diabetic ESRD ([@B89]; [@B99]). Diabetic organ injuries are essentially due to glucose metabolism defects. Therefore, normalizing blood glucose homeostasis is essential for diabetes therapies ([@B117]; [@B87]; [@B118]). However, recent clinical trials have indicated that the normalization of blood glucose levels is challenging in diabetes owing to an increased mortality risk, which is likely associated with frequent hypoglycemia ([@B49]). Consistent with this problem, blood glucose-lowering strategies aimed at normalizing the blood glucose level resulted in an increased mortality for the patients recruited to the intensive therapy group of the ACCORD trial ([@B49]). Therefore, to ameliorate the mortality associated with diabetic complications, additional therapeutic strategies to those that target proper blood glucose control are required.

Fibrosis is the final common pathway of progressive kidney diseases (similar to what occurs in other organs) and results in the destruction of the normal kidney structure and a significant deterioration in kidney function ([@B102]; [@B106]; [@B113]; [@B77]; [@B85]; [@B53]). Kidney fibrosis is induced by prolonged damage associated with impairment of the normal regulatory mechanisms for wound healing and an accumulation of extracellular matrix (ECM). Kidney fibroblasts play an important role in this fibrotic process, but the origin of the fibroblasts remains unclear and has become the focus of intense debate ([@B43]; [@B55]). Despite such a controversial discussion, significant heterogeneity for the matrix-producing fibroblasts is thought to exist ([@B55]), and diverse origins for the fibroblasts have been described, such as resident fibroblasts, resident pericytes, epithelial-to-mesenchymal transition (EMT), and endothelial-to-mesenchymal transition (EndMT) ([@B55]). The activation of such fibroblasts is important for the development of matrix-producing fibroblasts, and inhibiting this process could be a promising therapeutic target for diabetic kidney disease.

*N*-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), an endogenous anti-fibrotic peptide, is a substrate for angiotensin-converting enzyme, and the plasma level of AcSDKP has been shown to increase by fivefold after acute administration of the ACE-inhibitor (ACE-I) captopril ([@B4]). In this review, we focus on the use of AcSDKP to treat diabetic kidney disease by analyzing the potential mechanisms involving AcSDKP.

AcSDKP SYNTHESIS
================

AcSDKP is a tetrapeptide originally isolated from fetal calf bone marrow ([@B65]), and studies have recently focused on its anti-fibrotic property.

The details for the synthetic pathways responsible for the endogenous synthesis of AcSDKP are not yet clear, but the available information strongly suggests that thymosin β4 (Tβ4), one of the G-actin-sequestering peptides, is the most likely candidate for the AcSDKP precursor ([@B40]; [@B70]; **Figure [1](#F1){ref-type="fig"}**). In HeLa cells, when Tβ4 was knocked down using Tβ4 small interfering (si)RNA, there was significant suppression of AcSDKP expression ([@B70]). Furthermore, Lenfant and colleagues elegantly demonstrated that incubating radiolabeled \[^3^H\] Tβ4 with bone marrow cells or bone marrow lysate results in the formation of \[^3^H\]AcSDKP ([@B40]). AcSDKP is the N-terminal sequence of Tβ4 (**Figure [1](#F1){ref-type="fig"}**), and AcSDKP was thought to be synthesized by cleavage employing Asp-N endopeptidase ([@B40]). However, Asp-N is found only in bacteria and not in vertebrates. Therefore, [@B17] investigated other enzymes that may be responsible for Tβ4-mediated AcSDKP production, and they identified that prolyl oligopeptidase (POP; in some papers described as prolyl endopeptidase, PREP) is responsible for Tβ4-mediated AcSDKP production ([@B17]; **Figure [1](#F1){ref-type="fig"}**).

![**Synthesis and metabolism of AcSDKP.** Tβ4, a G-actin binding peptide, is cleaved by POP, and subsequently its N-terminal tetrapeptide, AcSDKP, is synthesized. AcSDKP is hydrolyzed and degraded by ACE. ACE-I may suppress miR-324-3p, which may inhibit protein expression of POP. Therefore, the mechanisms underlying the increased levels of AcSDKP by ACE-I may include both the suppression of degradation pathway and the induction of synthesis pathway of AcSDKP.](fphar-05-00070-g001){#F1}

In addition to AcSDKP, the Tβ4 precursor peptide displays anti-fibrotic and tissue-protective effects. Tβ4 is a 43 amino acid peptide (4.9 kDa) that can sequester G-actin and regulate its polymerization to F-actin ([@B48]; [@B42]). Tβ4 is expressed ubiquitously and exhibits various biologically significant activities ([@B48]; [@B42]). The utility of Tβ4 has been shown by [@B9], whereby exogenous intracardiac and intraperitoneal Tβ4 administration significantly restored cardiac function by neovascularization in an experimental myocardial infarction mouse model. Cardiac function restoration by Tβ4 has also been shown to occur by epicardial progenitor mobilization ([@B110]). Together, these reports suggest that Tβ4 exhibits organ-protective effects associated with anti-fibrosis and enhanced angiogenesis. It is unknown how AcSDKP contributes to Tβ4-mediated organ protection, but a recent paper has suggested that the anti-fibrotic effects of Tβ4 were lost when POP was inhibited in unilateral ureteral obstruction (UUO) models ([@B138]).

METABOLISM OF AcSDKP AND ACE STRUCTURE
======================================

As mentioned above, AcSDKP is produced by POP from the N-terminal peptide sequence of Tβ4, and AcSDKP is hydrolyzed in the presence of ACE (**Figure [1](#F1){ref-type="fig"}**). The plasma level of AcSDKP is minimal in normal conditions, and the AcSDKP concentration increased fivefold following administration of captopril ([@B4]). For ACE, there are two catalytic domains, namely the N-terminus and C-terminus, which contain the HEMGH consensus amino acid sequence. This motif is responsible for binding zinc and is crucial for enzymatic activity. These catalytic domains are responsible for the cleavage of target substrates (**Figure [2](#F2){ref-type="fig"}**; [@B127]; [@B6]). The overall amino acid homology between these two ACE catalytic domains is approximately 60%, and the homology reaches approximately 89% in the portions involved in catalysis ([@B6]). Studies of the genomic DNA exons and exon--intron boundaries have suggested that the ACE gene in higher organisms is the result of an ancient gene duplication event ([@B47]). The resultant ACE, which has two catalytic sites, is a so-called somatic ACE, an isozyme present in the plasma and generated by the endothelium, kidneys, and other somatic tissues. By contrast, the testis ACE, an ACE composed of only the C-terminal domain and not the N-terminal domain, is only expressed by developing male germ cells and is a smaller protein. This testis ACE, which lacks the N-terminal domain, is important because male mice lacking testis ACE exhibit fertility problems compared to wild-type mice ([@B58]; [@B29]; [@B33]). The testis ACE has been suggested to be the primordial form of ACE ([@B6]). These two ACE isozymes result from two separate promoter regions in the ACE gene ([@B46]; [@B63]).

![**Two catalytic domains of ACE and biological roles of ACE in tissue fibrosis.** In ACE, there are two catalytic sites. Angiotensin I exerts higher affinity for the C-terminal catalytic site of ACE. AcSDKP is a substrate for the N-terminal domain. ACE may induce tissue fibrosis by both the production of angiotensin II and the decreased level of AcSDKP. Captopril exhibits higher affinity for the N-terminal catalytic sites of ACE when compared with C-terminal catalytic sites. Furthermore, NaCl restriction on top of RAS-blockade may increase AcSDKP levels by unknown mechanisms.](fphar-05-00070-g002){#F2}

Such ACE gene duplication is suspected to have occurred early in evolution and might have occurred before mammalian differentiation ([@B47]). These two catalytic domains have been suggested to be functionally different (**Figure [2](#F2){ref-type="fig"}**). An ACE or an ACE-like enzyme is present in mammals, fish, worms, insects, crabs, and even ticks ([@B22]; [@B78]). Two ACE homologs, Ance and Acer, in *D. melanogaster* ([@B23]; [@B45]; [@B8]; [@B2]) have been studied comprehensively. In *D. melanogaster*, each of these enzymes has a single catalytic domain. An analysis of the gene structure and the enzymatic properties of each protein has revealed that Ance is similar to the C-terminal domain of somatic ACE and that Acer is more similar to the N-terminal domain of somatic ACE. Studies have suggested that the ACE gene duplication in vertebrates occurred approximately 330--350 million years ago ([@B23]). Both the N-terminal and C-terminal catalytic domains of ACE have been conserved over a longer period of time, thus suggesting that each ACE domain displays an important and different physiologic role.

Bradykinin is hydrolyzed at approximately the same ratio via both of these catalytic domains. Additionally, either the N-terminal or C-terminal catalytic domain can cleave angiotensin-I. The C-terminal domain has a fivefold higher affinity for angiotensin I (**Figure [2](#F2){ref-type="fig"}**; [@B127]; [@B105]; [@B6]). The affinity of angiotensin-I for the ACE catalytic site results in an interesting profile for blood pressure homeostasis. Mutant mice for each catalytic site of ACE, including the N-terminal (ACE^N^-KO; [@B34]) and C-terminal (ACE^C^-KO; [@B35]) domains, have normal blood pressure, but the underlying mechanisms by which blood pressure can be maintained are different, which is mainly due to the affinity of angiotensin I for the ACE catalytic domain. ACE^N^-KO mice have similar plasma levels of angiotensin I and renin compared to wild-type mice ([@B34]). In ACE^N^-KO mice, the C-terminal catalytic ACE domain is intact. Normal levels of angiotensin I and renin with a normal blood pressure indicate that the C-terminal domain of ACE is responsible for the majority of angiotensin II production in a normal state, thus resulting in no compensatory induction of renin or angiotensin I to maintain blood pressure in the ACE^N^-KO mice ([@B34]). In ACE^C^-KO mice, the mice with an intact N-terminal catalytic ACE domain have normal blood pressure similar to ACE^N^-KO mice, but the underlying mechanisms are completely different ([@B35]). Interestingly, the ACE^C^-KO mice have a significantly higher plasma angiotensin I level (approximately sevenfold) and plasma renin concentration (2.6-fold) compared to wild-type mice suggesting relatively lower catalytic effects of the N-terminal domain on angiotensin II production. Such an insufficient catalytic ability for converting angiotensin I to angiotensin II by the N-terminal ACE domain results in the compensatory induction of renin and subsequent elevation of angiotensin I. As a result, the angiotensin II levels are maintained to keep the blood pressure at normal levels.

In this regard, the affinity of each ACE-I for the ACE catalytic domains is structure dependent (**Figure [3](#F3){ref-type="fig"}**). The hydrophobic moieties of ACE-Is have been suggested to play an essential role in domain selectivity ([@B137]). For instance, captopril, the first ACE inhibitor used clinically, exhibits approximately a threefold greater affinity for the N-terminal domain compared to the C-terminal domain. By contrast, the relatively newer ACE-Is, such as enalaprilat, lisinopril, and trandolapril, display a higher affinity (approximately 4--20 times higher) for the C-terminal domain ([@B1]) because these drugs were developed as anti-hypertensive drugs (chemical structures of each ACE-I are shown in **Figure [3](#F3){ref-type="fig"}**).

![**Chemical structure of ACE inhibitors**.](fphar-05-00070-g003){#F3}

AcSDKP is hydrolyzed only by the N-terminal catalytic ACE domain (**Figure [2](#F2){ref-type="fig"}**). In fact, the testis (where the germinal-type ACE is expressed) is associated with a higher level of AcSDKP relative to other tissues ([@B112]; [@B34]). The role of the N-terminal ACE domain in the degradation of AcSDKP and its biological significance have been successfully reported by [@B67], who analyzed bleomycin-induced lung injury in wild-type, ACE^C^-KO, and ACE^N^-KO mice. The ACE^N^-KO mice had significantly less bleomycin-induced lung fibrosis as analyzed by lung histology and hydroxyproline level. Such protection against bleomycin-induced injury was not found in the ACE^C^-KO mice. Because the ACE^N^-KO mice had an elevated level of AcSDKP, the authors examined the effects of S-17092, a POP inhibitor. As mentioned above, POP is the enzyme responsible for AcSDKP production from Tβ4. As expected, the S-17092-treated ACE^N^-KO mice developed lung fibrosis similar to the wild-type mice. AcSDKP administration to the wild-type mice reduced bleomycin-induced lung fibrosis. This study revealed that AcSDKP elevation caused by inhibition of the N-terminal catalytic ACE domain leads to significant endogenous anti-fibrosis signaling in the lungs ([@B67]). Therefore, an N-terminal catalytic domain-specific ACE-I, such as RXP407 (**Figure [2](#F2){ref-type="fig"}**), may have great potential as an antifibrotic therapy ([@B51]; [@B119]; [@B59]; [@B3]).

CELL CYCLE CONTROL AND AcSDKP
=============================

AcSDKP is a naturally occurring inhibitor of hematopoietic stem cell proliferation that prevents entry into the S phase from G1 in the cell cycle ([@B126]). The effect of AcSDKP on cell proliferation is not limited to hematopoietic stem cells, and AcSDKP has been shown to inhibit human mesangial cell proliferation ([@B52]) as well as renal ([@B50]) and cardiac fibroblast ([@B100]) proliferation. Moreover, AcSDKP has been shown to inhibit collagen deposition in mouse cardiac fibroblasts ([@B100]). The detailed mechanisms for AcSDKP-mediated cell cycle regulation are not yet clear, but AcSDKP may inhibit serum-stimulated extracellular signal-regulated kinase (ERK) signaling. Alternatively, as we have shown in mesangial cells, AcSDKP may inhibit cell cycle progression/DNA synthesis stimulated by serum or platelet-derived growth factor-B in human mesangial cells through the induction of cell cycle regulators, such as p53, p27^kip1^, and p21^cip1^, together with the inhibition of cyclin D1 ([@B52]). Additionally, p53 induces the expression of p21^cip1^ and p27^kip1^, together with inhibition of the cell cycle at G1/S ([@B52]). In mesangial cells, p53 is a key regulator for the induction of these cell cycle modulators ([@B52]). Supporting the role of p53 in cell cycle inhibition, AcSDKP inhibits cell cycle progression in normal cells, but AcSDKP does not suppress progression in chronic myeloid leukemia (CML) progenitors in long-term culture ([@B14]) as these cells frequently exhibit p53 deficiency ([@B18]; [@B30]; [@B7]). Indeed, siRNA-mediated gene silencing of p53 in human mesangial cells has been shown to abolish AcSDKP-mediated cell cycle inhibition of mesangial cells proliferation ([@B52]). These data suggest that AcSDKP inhibits mesangial cell proliferation through p53 induction.

ANTI-FIBROTIC EFFECTS OF AcSDKP
===============================

AcSDKP reportedly exhibits anti-fibrotic organ-protective effects in various experimental models ([@B32]; [@B88]; [@B15]; [@B138]). Additionally, we have reported that AcSDKP prevents mesangial matrix expansion in diabetic db/db mice ([@B109]). [@B16] reported that endogenous levels of AcSDKP play an important role for anti-fibrotic effects. Fibroblasts play an important role in tissue fibrosis. As mentioned previously, AcSDKP has been shown to suppress the proliferation of renal ([@B50]) and cardiac fibroblasts ([@B100]).

The local accumulation of pro-fibrotic cytokines in the microenvironment following kidney insult results in ECM-producing cell activation, which is essential for renal fibrogenesis. The fundamental matrix-producing cells, which generate a large quantity of interstitial matrix components (including fibronectin and type I and type III collagens), are indeed fibroblasts ([@B114]). Activated fibroblasts (or myofibroblasts) would be an important source of ECM-producing renal cells, but almost all cell types (either resident or non-resident kidney cells) are responsible for ECM production ([@B55]). Those cells include resident fibroblasts, tubular epithelial cells, vascular smooth muscle cells, and a subset of invading macrophages. In such a process, the profibrotic cytokine, transforming-growth factor-(TGF)-β, has a fundamental role. Consistent with this information, blocking either TGF-β or the TGF-β-stimulated Smad transcriptional factor signaling pathway has been shown to exhibit anti-fibrotic effects ([@B11]; [@B81]; [@B54], [@B56]; [@B97]; [@B116]; [@B44]; [@B62]; [@B107]; [@B21]). In fibrotic kidneys, activated fibroblasts express α smooth muscle actin (αSMA) and are often called myofibroblasts, which display unique contractile properties ([@B114]). The renal myofibroblast is thought to be an activated fibroblast that plays a role during kidney fibrosis. Thus, numerous studies have been performed to analyze the origin, activation, and regulation of these matrix-producing myofibroblasts ([@B38]; [@B80]).

There are five well-reported sources of matrix-producing myofibroblasts (**Figure [4](#F4){ref-type="fig"}**), including activated resident fibroblasts, differentiated pericytes, recruited circulating bone marrow-derived cells, and mesenchymal cells transformed from tubular epithelial cells or endothelial cells ([@B5]). There are intense debates regarding such diverse myofibroblast-generating pathways and their contribution in renal fibrosis ([@B136]). However, even though many studies focused on analyzing the number of myofibroblast and their origin, the most important clue to understand kidney fibrosis is the functional interaction and effects of these fibroblasts and resident kidney cells. Thus, Kalluri and colleagues reported a breakthrough observation regarding the origin and function of kidney myofibroblasts ([@B64]). In a recent publication analyzing a UUO model by [@B64], the accumulation of myofibroblasts in the kidneys arose from predominantly two different origins as follows: local proliferation of resident kidney fibroblasts (\~50%) and bone marrow-derived cells without any evidence of proliferation in the kidney (35%). Bone marrow-derived mesenchymal stem cells can differentiate into myofibroblasts in the presence of TGF-β1. Surprisingly, while the loss of *Tgfbr2* in αSMA^+^ cells led to an approximately 56% reduction in the accumulation of myofibroblasts, only an approximately 29% reduction in kidney fibrosis was found. Additionally, F4/80^+^ and CD11b^+^ macrophage recruitment was significantly reduced in mice lacking *Tgfbr2* in their αSMA^+^ cells. The loss of *Tgfbr2 in* αSMA^+^ cells likely affects myofibroblasts specifically derived through differentiation.

![**Diverse origins of myofibroblasts.** Kidney fibrosis is a well-coordinated event originating from various sources: **(1)** tubular epithelial cells; **(2)** interstitial resident fibroblasts; **(3)** endothelial cells; **(4)** bone marrow-derived cells; and **(5)** pericytes that contribute to myofibroblast activation/formation.](fphar-05-00070-g004){#F4}

The administration of AcSDKP ameliorated kidney fibrosis and glomerular sclerosis in hypertensive rats as well as in diabetic and non-diabetic kidney disease models without altering blood pressure ([@B92]; [@B101]). While many reports have consistently shown strong anti-fibrotic effects *in vivo* and the direct effects of AcSDKP on culture fibroblast *in vitro*, it is still unclear how AcSDKP affects fibroblast activation or differentiation into myofibroblasts. There were two publications that describe the association between AcSDKP and myofibroblast differentiation. The first report by [@B91] found that human cardiac fibroblasts treated with TGF-β1 transform into myofibroblasts as indicated by increased expression of αSMA and a higher expression of the embryonic isoform of smooth muscle myosin compared to untreated cells, and this report also demonstrated that AcSDKP inhibited TGF-β1-induced differentiation of cardiac fibroblasts into myofibroblasts. The second report by [@B134] demonstrated that AcSDKP inhibits the TGF-β1-induced pulmonary fibroblast transformation into myofibroblasts and myofibroblast localization in siliconic nodules in the lung. These reports described the suppressive effects of AcSDKP on myofibroblast differentiation, but further investigations are needed to reveal both the specific origin of myofibroblasts and specific target molecules affected by AcSDKP. Regard with this, we have recently shown that AcSDKP may inhibit EndMT via restoration of fibroblast growth factor receptor (FGFR) and FGFR-associated induction of microRNA let-7, the critical factors for the maintenance of endothelial homeostasis ([@B19]), in diabetic mice kidneys ([@B82]).

We and others have shown that AcSDKP inhibits TGF-β-induced Smad2 phosphorylation (**Figure [5](#F5){ref-type="fig"}**), and the anti-TGF-β/Smad pathway is the key to understand its antifibrotic effect ([@B94]; [@B54]). Additionally, this observation identifies AcSDKP as the first endogenous circulatory molecule that specifically inhibits TGF-β-induced receptor regulated (R)-Smad phosphorylation. The Smads are transcription factors specific to the TGF-β superfamily and play a central role in signal transduction from cell membrane receptors ([@B11]; [@B81]). Depending on their role in signaling, Smads are classified into three categories as follows: (a) receptor-regulated Smads, or R-Smads (Smad2 and 3); (b) common Smad, or co-Smad (Smad4); and (c) inhibitory Smads, or I-Smads (Smad6 and 7). Once TGF-β binding occurs, the type II receptor physically interacts with the type I receptor inducing the phosphorylation of serine residues on the type I receptor (**Figure [5](#F5){ref-type="fig"}**; [@B131]). The phosphorylated type I receptor phosphorylates R-Smads, and phosphorylated R-Smads subsequently interact with co-Smads in the cytoplasm (**Figure [5](#F5){ref-type="fig"}**). The R-Smad and co-Smad heterodimers then translocate into the nucleus (**Figure [5](#F5){ref-type="fig"}**) with the help of importin-β ([@B133]; [@B60]). The Smad heterodimers bind to the Smad-binding elements of the target promoter DNA regions (**Figure [5](#F5){ref-type="fig"}**). By contrast, I-Smads localize to the nucleus (**Figure [5](#F5){ref-type="fig"}**; [@B54]), and nuclear-localized I-Smads translocate to the cytoplasm following TGF-β stimulation. I-Smad is believed to competitively inhibit R-Smad phosphorylation by the type I receptor or induce ubiquitination of the receptors by I-Smad interaction with E3 ligase smurf proteins ([@B84]; [@B28]; [@B41]; [@B115]).

![**AcSDKP is an anti-TGF-β/Smad peptide.** Once TGF-β binds to TGF-β receptors on the cell membrane, the TGF-β and TGF-β-receptor interaction induces phosphorylation of receptor-regulated (R)-Smads. Phosphorylated R-Smads interact with the common (co)-Smad in the cytoplasm. These Smad heterodimers in the nucleus then bind to the genomic promoter region of DNA, which is called the Smad-binding element (SBE). AcSDKP may induce Smad7 gene expression, protein stabilization, or translocation from the nucleus of cells to the cytoplasm as well as inhibit phosphorylation of R-Smads by TGF-β receptors. However, detailed mechanisms are not yet known.](fphar-05-00070-g005){#F5}

Although the underlying mechanisms by which AcSDKP inhibits TGF-β-induced phosphorylation of R-Smad are not completely known, I-Smads are likely involved at least in part (**Figure [5](#F5){ref-type="fig"}**). We have shown that the incubation of human mesangial cells in the presence of AcSDKP results in the cytoplasmic translocation of Smad7 (one of the I-Smads) in the absence of TGF-β stimulation (**Figure [5](#F5){ref-type="fig"}**; [@B54]). Several studies have reported an increased Smad7 level *in vivo* following AcSDKP administration supporting the Smad7-mediated anti-TGF-β/Smad effects of AcSDKP (**Figure [4](#F4){ref-type="fig"}**; [@B88]; [@B68]). Alternatively the suppression of TGF-β type I receptor levels via microRNA let-7 ([@B19]) induced by AcSDKP ([@B82]) may contribute to the AcSDKP-inhibited R-Smad phosphorylation.

AcSDKP AND APOPTOSIS
====================

AcSDKP was originally identified as a regulator of hematopoietic stem cells ([@B65]; [@B96], [@B95]). AcSDKP can suppress apoptosis of hematopoietic cells induced by cytotoxic stresses, such as chemotherapy ([@B10]; [@B39]), radiation ([@B125]; [@B26]), high temperature ([@B129]; [@B128], [@B130]), and photofrin II-mediated phototherapy ([@B24]). Enhanced apoptosis is linked to tissue fibrosis, and inhibition of the apoptosis pathway has been associated with anti-fibrosis therapy in several organs ([@B36]; [@B25]; [@B104]; [@B27]).

AcSDKP AND INFLAMMATION
=======================

Inflammation is essential for tissue repair, except in embryos where tissue repair can be completed without typical inflammation ([@B13]; [@B98]). In adults, organ inflammation is closely linked to tissue repair, the regeneration of parenchymal cells and filling in tissue defects with fibrous tissue, such as scar formation ([@B132]). Moreover, progressive fibrosis with sustained inflammation is recognized as a type of chronic wound with normal wound healing defects ([@B75]). In experimental animal models, the amelioration of tissue fibrosis by AcSDKP has been associated with inhibition of inflammation in the kidneys, heart, and liver ([@B135]; [@B88]; [@B90]; [@B68]; [@B108]; [@B72]; [@B20]). AcSDKP suppresses monocyte chemoattractant protein-1 (MCP-1; [@B124]), one of the key chemokines that regulates macrophage infiltration. AcSDKP has been shown to inhibit the key pro-inflammatory transcriptional factor, NFκB, and associated chemokines ([@B83]; [@B37]). However, another report has described AcSDKP-induced MCP-1 expression and an accumulation of Mac1-positive cells in a model of surgically induced hind-limb ischemia ([@B122]). In their report, AcSDKP-induced MCP-1 expression is the key for AcSDKP-mediated tissue repair and post-ischemic neovascularization based on MCP-1 knockout mice ([@B122]), thereby suggesting that AcSDKP does not simply inhibit inflammation but may regulate normal tissue repair and appropriately control inflammation.

AcSDKP AND ANGIOGENESIS
=======================

Angiogenesis is essential for tissue homeostasis and to promote tissue repair. AcSDKP ([@B74]; [@B123]; [@B32]) and its precursor peptide, Tβ4 ([@B79]; [@B48]; [@B57]; [@B93]) have been shown to enhance angiogenesis and exhibit anti-fibrotic effects associated with normalization of organ function ([@B110]). AcSDKP improves skin flap survival and accelerates wound healing ([@B32]). The association between tumor angiogenesis and the levels of Tβ4 and AcSDKP has been studied by [@B126], and these authors have proposed that high levels of Tβ4 and AcSDKP are linked to tumor progression in hematologic malignancies ([@B69], [@B73], [@B71], [@B70]). Angiogenesis plays a pivotal role in cancer development ([@B86]; [@B31]), and the AcSDKP level has been shown to be higher in hematologic malignancies and solid neoplasms ([@B69], [@B73], [@B71], [@B70]). An association between the AcSDKP level and tumor angiogenesis was observed in these previous studies, but the pathophysiological significance of this result was not clearly shown.

PERSPECTIVE
===========

As described above, AcSDKP has emerged as an attractive anti-fibrotic molecule to combat fibroproliferative diseases, including diabetic nephropathy. However, other than its production from Tβ4 by POP and degradation by ACE, the physiological regulation of AcSDKP and its significance in pathogenesis are largely unknown. In this regard, recent publications have provided new clues about the regulation of AcSDKP in experimental animals and in patients treated with ACE-I.

Recently, microRNAs have been implicated as key players in physiological homeostasis, and dysregulation of microRNAs results in pathological conditions, such as tissue fibrosis ([@B43]; [@B111]). A fibroblast-activating pathway has also been shown to be associated with microRNA dysregulation ([@B43]; [@B111]). [@B76] recently found that one of the microRNAs, miR-324-3p, is significantly increased in the glomeruli of Munich Wistar Frömter (MWF) rats, which is a model for spontaneous progressive nephropathy, and they reported that increased expression of miR-324-3p is present in glomerular podocytes, parietal cells in Bowman's capsule, and most abundantly in cortical tubules. Interestingly, the predicted target for miR-324-3p is POP, and overexpression of a miR-324-3p mimetic in culture decreased POP protein expression (**Figure [1](#F1){ref-type="fig"}**). High miR-324-3p expression in MWF rats was associated with reduced POP expression in glomeruli and tubules as well as suppressed urine AcSDKP levels and increased collagen deposition. Surprisingly, the ACE-I lisinopril, suppressed miR-324-3p expression and subsequently increased renal POP expression as well as plasma and urine AcSDKP levels, which were associated with the restoration of a normal kidney structure. This report revealed that the endogenous AcSDKP synthesis pathway is indeed enhanced by ACE-I, regulated by miR-324-3p suppression and associated with induction of POP, the key enzyme for AcSDKP synthesis.

Another important finding in AcSDKP regulation has been reported in a recent clinical trial. Sodium intake has been shown to worsen the clinical outcome of renal diseases ([@B120]). [@B61] focused on potential organ-protective effects of AcSDKP and investigated whether sodium restriction in addition to renin--angiotensin system (RAS) blockade results in increased levels of AcSDKP. These authors enrolled 46 non-diabetic chronic kidney disease patients (age 50 ± 13 years) with overt proteinuria and mild to moderate renal insufficiency. The patients were analyzed using a crossover design and subjected to a double-blind experiment for a 6-week study period with a regular sodium diet (194 ± 49 mmol sodium/day) or a low sodium diet (102 ± 52 mmol sodium/day) and either lisinopril (40 mg/day; single RAS-blockade) or lisinopril plus valsartan (320 mg/day; dual blockade). Surprisingly, they found that sodium restriction significantly increased the plasma level of AcSDKP during either single or dual RAS-blockade (**Figure [2](#F2){ref-type="fig"}**). The AcSDKP level was associated with sodium restriction but independent of sex, age, renal function, blood pressure, body mass index, single RAS-blockade, dual RAS-blockade, treatment sequence, or other dietary factors (calcium and protein intake). This report is indeed surprising because sodium restriction would decrease the circulatory plasma volume, and a decreased plasma volume may be associated with an enhanced RAS feedback, thus resulting in a suppressed AcSDKP level. To understand how sodium restriction in addition to RAS-blockade may alter the AcSDKP level, further investigation is needed. Nevertheless, [@B61] study showed the novel regulation of AcSDKP by a mechanism other than an ACE-I in humans. The association between salt intake and AcSDKP levels without RAS-blockade remains unknown and requires future analysis ([@B61]). This study may provide some hints for the physiological regulation of AcSDKP in humans, and such knowledge may reveal the AcSDKP level required for anti-fibrotic effects in human kidney diseases, including diabetic nephropathy.

CONCLUSION
==========

In this review, we summarized the findings regarding AcSDKP focusing on its physiological regulation, function, and potential as an anti-fibrotic drug. The beneficial effects of AcSDKP could be significant for treating patients with fibroproliferative diseases, including diabetic nephropathy. Clearly, future studies will be required to establish how we can utilize the attractive anti-fibrotic effects of AcSDKP in the clinic and to monitor safety profiling of AcSDKP use. Nevertheless, AcSDKP will emerge as a valuable anti-fibrotic endogenous molecule (**Figure [6](#F6){ref-type="fig"}**) with the potential to cure devastating fibroproliferative diseases, including diabetic nephropathy.

![**Beneficial effects of AcSDKP in the process of tissue repair.** AcSDKP exhibits multiple functions shown above, such as regulation of inflammation as well as anti-fibrotic, anti-apoptotic, and pro-angiogenic activities. Therefore, AcSDKP could be a candidate target molecule to combat kidney fibrosis in diabetes.](fphar-05-00070-g006){#F6}
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